Miller D R, Martineau R J, O'Brien H, Hull K A, Oliveras L, Hindmarsh T, Greenway D
Department of Anesthesia, Ottawa General Hospital, Ontario, Canada.
Anesth Analg. 1993 May;76(5):1040-6. doi: 10.1213/00000539-199305000-00023.
A randomized, placebo-controlled study was conducted in 60 ASA Class I, II, and III patients to determine the dose response of alfentanil in moderating the cardiovascular and catecholamine response to tracheal intubation (INT). Patients were randomly allocated into one of four groups to receive either 15 micrograms/kg alfentanil (A15), 30 micrograms/kg alfentanil (A30), 45 micrograms/kg alfentanil (A45), or normal saline (control), given intravenously (i.v.) before induction of anesthesia. One minute after administration of 4.0 mg/kg thiopental and 1.5 mg/kg succinylcholine i.v., tracheal intubation was performed using direct laryngoscopy. In response to INT, increases in heart rate, systolic blood pressure, and systemic vascular resistance occurred in the control group. These changes were significantly more than corresponding changes of heart rate, systolic blood pressure, and systemic vascular resistance in all three alfentanil groups (P < 0.05). In contrast, cardiac index and ejection fraction decreased moderately in every group during the study period, but there were no differences among groups with respect to either cardiac index or ejection fraction at corresponding times following INT. In the control group, epinephrine and norepinephrine serum concentrations increased by 152 +/- 52% and 58 +/- 62%, respectively, following INT (different from A30 and A45, P < 0.05). However, up to a dose of 30 micrograms/kg (A30), a dose-dependent decrease in the maximum percent changes of both epinephrine and norepinephrine occurred in response to INT. A larger dose of alfentanil was no more efficacious as the catecholamine response to tracheal intubation was not significantly different when comparing the A45 and A30 groups.(ABSTRACT TRUNCATED AT 250 WORDS)
一项随机、安慰剂对照研究在60例美国麻醉医师协会(ASA)分级为I、II和III级的患者中进行,以确定阿芬太尼在减轻气管插管(INT)引起的心血管和儿茶酚胺反应中的剂量反应。患者被随机分为四组之一,在麻醉诱导前静脉注射15微克/千克阿芬太尼(A15)、30微克/千克阿芬太尼(A30)、45微克/千克阿芬太尼(A45)或生理盐水(对照组)。静脉注射4.0毫克/千克硫喷妥钠和1.5毫克/千克琥珀酰胆碱1分钟后,使用直接喉镜进行气管插管。对照组在INT后心率、收缩压和全身血管阻力增加。所有三个阿芬太尼组的心率、收缩压和全身血管阻力的相应变化明显小于对照组(P<0.05)。相比之下,在研究期间每组的心指数和射血分数均适度下降,但在INT后的相应时间,各组在心指数或射血分数方面没有差异。在对照组中,INT后肾上腺素和去甲肾上腺素血清浓度分别增加了152±52%和58±62%(与A30和A45组不同,P<0.05)。然而,高达30微克/千克(A30)的剂量,INT后肾上腺素和去甲肾上腺素的最大百分比变化呈剂量依赖性下降。当比较A45组和A30组时,更大剂量的阿芬太尼在减轻气管插管引起的儿茶酚胺反应方面并无更显著效果(摘要截断于250字)